Want to join the conversation?
$ILMN reported preliminary 3Q16 revenue of about $607MM, up 10% from $550MM in 3Q15. This estimate is lower than 3Q guidance of $625-630MM. The shortfall in quarterly revenue was driven by a larger than anticipated YoverY decline in high throughput sequencing instruments. Hence, $ILMN sees 4Q16 revenue to be flat to slightly up sequentially.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)